173 related articles for article (PubMed ID: 35760783)
21. Inhibition of esophageal-carcinoma cell proliferation by genistein via suppression of JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways.
Gao J; Xia R; Chen J; Gao J; Luo X; Ke C; Ren C; Li J; Mi Y
Aging (Albany NY); 2020 Apr; 12(7):6240-6259. PubMed ID: 32276266
[TBL] [Abstract][Full Text] [Related]
22. Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest.
Giono LE; Manfredi JJ
Mol Cell Biol; 2007 Jun; 27(11):4166-78. PubMed ID: 17371838
[TBL] [Abstract][Full Text] [Related]
23. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
Fortunato O; Boeri M; Moro M; Verri C; Mensah M; Conte D; Caleca L; Roz L; Pastorino U; Sozzi G
Cell Death Dis; 2014 Dec; 5(12):e1564. PubMed ID: 25501825
[TBL] [Abstract][Full Text] [Related]
24. Alterations of the p53, Rb and p27 tumor suppressor pathways in diffuse large B-cell lymphomas.
Bai M; Tsanou E; Skyrlas A; Sainis I; Agnantis N; Kanavaros P
Anticancer Res; 2007; 27(4B):2345-52. PubMed ID: 17695524
[TBL] [Abstract][Full Text] [Related]
25. Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma.
Andrews A; Warner K; Rodriguez-Ramirez C; Pearson AT; Nör F; Zhang Z; Kerk S; Kulkarni A; Helman JI; Brenner JC; Wicha MS; Wang S; Nör JE
Clin Cancer Res; 2019 Mar; 25(5):1588-1600. PubMed ID: 30498096
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas.
Nör F; Warner KA; Zhang Z; Acasigua GA; Pearson AT; Kerk SA; Helman JI; Sant'Ana Filho M; Wang S; Nör JE
Clin Cancer Res; 2017 Feb; 23(4):1036-1048. PubMed ID: 27550999
[No Abstract] [Full Text] [Related]
27. A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation.
Brekman A; Singh KE; Polotskaia A; Kundu N; Bargonetti J
Breast Cancer Res; 2011 Jan; 13(1):R3. PubMed ID: 21223569
[TBL] [Abstract][Full Text] [Related]
28. Aciculatin induces p53-dependent apoptosis via MDM2 depletion in human cancer cells in vitro and in vivo.
Lai CY; Tsai AC; Chen MC; Chang LH; Sun HL; Chang YL; Chen CC; Teng CM; Pan SL
PLoS One; 2012; 7(8):e42192. PubMed ID: 22912688
[TBL] [Abstract][Full Text] [Related]
29. Long non-coding RNA SNHG16 promotes proliferation and inhibits apoptosis of diffuse large B-cell lymphoma cells by targeting miR-497-5p/PIM1 axis.
Zhu Q; Li Y; Guo Y; Hu L; Xiao Z; Liu X; Wang J; Xu Q; Tong X
J Cell Mol Med; 2019 Nov; 23(11):7395-7405. PubMed ID: 31483572
[TBL] [Abstract][Full Text] [Related]
30. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
Gamble LD; Kees UR; Tweddle DA; Lunec J
Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
[TBL] [Abstract][Full Text] [Related]
32. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.
Wang S; Sun W; Zhao Y; McEachern D; Meaux I; Barrière C; Stuckey JA; Meagher JL; Bai L; Liu L; Hoffman-Luca CG; Lu J; Shangary S; Yu S; Bernard D; Aguilar A; Dos-Santos O; Besret L; Guerif S; Pannier P; Gorge-Bernat D; Debussche L
Cancer Res; 2014 Oct; 74(20):5855-65. PubMed ID: 25145672
[TBL] [Abstract][Full Text] [Related]
33. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
35. Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53.
Ou WB; Lu M; Eilers G; Li H; Ding J; Meng X; Wu Y; He Q; Sheng Q; Zhou HM; Fletcher JA
Br J Cancer; 2016 Nov; 115(10):1253-1263. PubMed ID: 27736841
[TBL] [Abstract][Full Text] [Related]
36. The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway.
Wan W; Hou Y; Wang K; Cheng Y; Pu X; Ye X
Cell Death Dis; 2019 Mar; 10(3):248. PubMed ID: 30867411
[TBL] [Abstract][Full Text] [Related]
37. Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo.
Gu J; Wang B; Liu Y; Zhong L; Tang Y; Guo H; Jiang T; Wang L; Li Y; Cai L
Eur J Cancer; 2014 Apr; 50(6):1184-94. PubMed ID: 24447832
[TBL] [Abstract][Full Text] [Related]
38. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
39. LUCAT1 promotes colorectal cancer tumorigenesis by targeting the ribosomal protein L40-MDM2-p53 pathway through binding with UBA52.
Zhou Q; Hou Z; Zuo S; Zhou X; Feng Y; Sun Y; Yuan X
Cancer Sci; 2019 Apr; 110(4):1194-1207. PubMed ID: 30690837
[TBL] [Abstract][Full Text] [Related]
40. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]